Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Callahan, Margaret K.
842  Ergebnisse:
Personensuche X
?
1

Integration of peripheral blood‐ and tissue‐based biomarker..:

Vanguri, Rami S ; Smithy, James W ; Li, Yanyun...
The Journal of Pathology.  261 (2023)  3 - p. 349-360 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Beyond the 5‐year milestone: Long‐term survivorship of mela..:

Loo, Kimberly ; Kalvin, Hannah L. ; Panageas, Katherine S....
Pigment Cell & Melanoma Research.  36 (2023)  3-4 - p. 314-320 , 2023
Link: https://doi.org/10.1111/..
 
?
3

Phase Ib Trial of Phenformin in Patients with V600-mutated ..:

Chapman, Paul B. ; Klang, Mark ; Postow, Michael A....
Cancer Research Communications.  3 (2023)  12 - p. 2447-2454 , 2023
Link: https://doi.org/10.1158/..
 
?
4

Decision-Making and Health-Related Quality of Life in Patie..:

Atkinson, Thomas M ; Hay, Jennifer L ; Young Kim, Soo...
The Oncologist.  28 (2023)  4 - p. 351-357 , 2023
Link: https://doi.org/10.1093/..
 
?
5

A topic modeling approach reveals the dynamic T cell compos..:

Peng, Xiyu ; Lee, Jasme ; Adamow, Matthew...
Cell Reports Methods.  3 (2023)  8 - p. 100546 , 2023
Link: https://doi.org/10.1016/..
 
?
6

Fundamental immune–oncogenicity trade-offs define driver mu..:

Hoyos, David ; Zappasodi, Roberta ; Schulze, Isabell...
Nature.  606 (2022)  7912 - p. 172-179 , 2022
Link: https://doi.org/10.1038/..
 
?
7

Tumor MHC Class I Expression Associates with Intralesional ..:

Pourmaleki, Maryam ; Jones, Caitlin J. ; Ariyan, Charlotte E....
Cancer Immunology Research.  10 (2022)  3 - p. 303-313 , 2022
Link: https://doi.org/10.1158/..
 
?
8

Author Correction: Fundamental immune–oncogenicity trade-of..:

Hoyos, David ; Zappasodi, Roberta ; Schulze, Isabell...
Nature.  606 (2022)  7914 - p. E5-E5 , 2022
Link: https://doi.org/10.1038/..
 
?
9

Safety, tolerability and efficacy of agonist anti-CD27 anti..:

Sanborn, Rachel E ; Pishvaian, Michael J ; Callahan, Margaret K...
Journal for ImmunoTherapy of Cancer.  10 (2022)  8 - p. e005147 , 2022
Link: https://doi.org/10.1136/..
 
?
10

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist ..:

Yap, Timothy A. ; Gainor, Justin F. ; Callahan, Margaret K....
Clinical Cancer Research.  28 (2022)  17 - p. 3695-3708 , 2022
Link: https://doi.org/10.1158/..
 
?
11

Inherited PD-1 deficiency underlies tuberculosis and autoim..:

Ogishi, Masato ; Yang, Rui ; Aytekin, Caner...
Nature Medicine.  27 (2021)  9 - p. 1646-1654 , 2021
Link: https://doi.org/10.1038/..
 
?
12

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recu..:

Ready, Neal E. ; Ott, Patrick A. ; Hellmann, Matthew D....
Journal of Thoracic Oncology.  15 (2020)  3 - p. 426-435 , 2020
Link: https://doi.org/10.1016/..
 
?
13

Defining tumor resistance to PD-1 pathway blockade: recomme..:

Kluger, Harriet M. ; Tawbi, Hussein A. ; Ascierto, Maria L....
Journal for ImmunoTherapy of Cancer.  8 (2020)  1 - p. e000398 , 2020
Link: https://doi.org/10.1136/..
 
?
14

Clinical implications of drug‐induced liver injury in early..:

Mondaca, Sebastian P. ; Liu, Dazhi ; Flynn, Jessica R....
Cancer.  126 (2020)  22 - p. 4967-4974 , 2020
Link: https://doi.org/10.1002/..
 
?
15

Myocarditis Surveillance in Patients with Advanced Melanoma..:

Lee Chuy, Katherine ; Oikonomou, Evangelos K. ; Postow, Michael A....
The Oncologist.  24 (2019)  5 - p. e196-e197 , 2019
Link: https://doi.org/10.1634/..
 
1-15